Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 3Completed 3Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Breast Neoplasms 63Neoplasms 59Leukemia, Myeloid, Acute 59Multiple Myeloma 53Colorectal Neoplasms 48Lymphoma 46Recurrence 45Carcinoma, Hepatocellular 45Stomach Neoplasms 43Pancreatic Neoplasms 40Neoplasm Metastasis 39Prostatic Neoplasms 34Melanoma 34Leukemia 30Lymphoma, Non-Hodgkin 27Lymphoma, B-Cell 27Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 24Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 21Esophageal Neoplasms 21Carcinoma, Renal Cell 20Myelodysplastic Syndromes 19Leukemia, Lymphocytic, Chronic, B-Cell 19Hematologic Neoplasms 19Colonic Neoplasms 19Head and Neck Neoplasms 18Lymphoma, Mantle-Cell 17

Interventions

CCT239065 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Thyroid Carcinoma, Anaplastic × Clear all
NCT05102292 2023-08-21

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Shanghai Henlius Biotech

Phase 1/2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡